English
Home > Products > 56-40-6

China 56-40-6 Factory

Our development depends on the advanced equipment, excellent talents and continuously strengthened technology forces for 56-40-6,CAS NO 56-40-6,Glycine API,Glycine, Presently, we are looking forward to even larger cooperation with overseas clients based on mutual benefits. Make sure you come to feel no cost to make contact with us for more information.
56-40-6, We've exported our solutions all over the world, especially the USA and European countries. Furthermore, all of our merchandise are manufactured with advanced equipment and strict QC procedures to ensure high quality.If you are interested in any of our products and solutions, please don't hesitate to contact us. We are going to try our best to meet your needs.

Related Products

Hot Products

  • Teprenone

    Teprenone

    Product Name:Teprenone
    Molecular Formula:C23H38O
    Molecular Weight:330.55
    CAS Registry Number:6809-52-5
  • Boc-D-prolinol

    Boc-D-prolinol

    Product Name:Boc-D-prolinol
    Molecular Formula:C10H19NO3
    Molecular Weight:201.26
    CAS Registry Number:83435-58-9
  • 20-(tert-Butoxy)-20-oxoicosanoic acid

    20-(tert-Butoxy)-20-oxoicosanoic acid

    Product Name:20-(tert-Butoxy)-20-oxoicosanoic acid
    Molecular Formula:C24H46O4
    Molecular Weight:398.62
    CAS Registry Number:683239-16-9
  • Secnidazole

    Secnidazole

    Product Name:Secnidazole
    Molecular Formula:C7H11N3O3
    Molecular Weight;185.18
    CAS Registry Number;3366-95-8
  • 3-(2-Bromo-1-Oxopropyl)-Spiro[2H-1,3-Benzoxazine-2,1'Cyclohexan]-4(3H)-One

    3-(2-Bromo-1-Oxopropyl)-Spiro[2H-1,3-Benzoxazine-2,1'Cyclohexan]-4(3H)-One

    Molecular Formula C16H18BrNO3 Molecular Weight 352.21 CAS Registry Number 158299-05-9
  • EMEDASTINE FUMARATE

    EMEDASTINE FUMARATE

    Product Name:EMEDASTINE FUMARATE
    Molecular Formula:C25H34N4O9
    Molecular Weight;534.56
    CAS Registry Number;87233-62-3
  • Related Blog
  • Reviews

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • CAS 148553-50-8 What is Pregabalin?

    Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses within the brain that cause seizures. Pregabalin also affects chemicals within the brain that send pain signals across the systema nervosum.

  • What Is Misoprostol Used For?

    Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer, the prevention of anti-inflammatory induced peptic ulcer and the prevention of early pregnancy.It has the function of inhibiting the secretion of gastric acid and preventing the formation of ulcer, thus protecting the gastric mucosa...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 56-40-6

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept